Universitätsklinik für Medizinische Onkologie, Inselspital
Welcome,         Profile    Billing    Logout  
 1 Trial 
11 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Addeo, Alfredo
AMAZE-lung, NCT05601973 / 2021-002337-42: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

Recruiting
2
60
Europe
Amivantamab, Lazertinib, Zirabev
ETOP IBCSG Partners Foundation, Janssen Pharmaceuticals
Non Small Cell Lung Cancer
03/26
09/26
CHESS, NCT03965468 / 2018-003011-22: Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC

Recruiting
2
96
Europe
Durvalumab, Imfinzi, Carboplatin, Paclitaxel, Stereotactic body radiation therapy (SBRT), Surgical resection - definitive local treatment., Radical radiotherapy - definitive local treatment., Tremelimumab
ETOP IBCSG Partners Foundation, AstraZeneca
Non-small Cell Lung Cancer, Stage IV, Oligometastasis
08/26
12/26
AMBER, NCT06068153: AMG510 (Sotorasib) Plus Lenvatinib as Second-line Treatment in Patients With KRASG12C Mutant, Metastatic NSCLC

Withdrawn
2
47
Europe
Sotorasib, Lenvatinib
ETOP IBCSG Partners Foundation, Amgen, Eisai Inc.
Metastatic Non Small Cell Lung Cancer, KRAS G12C
09/26
12/26
UNICORN, NCT05421936: Osimertinib for NSCLC With Uncommon EGFR Mutations

Suspended
N/A
100
RoW
Osimertinib
Sheba Medical Center, AstraZeneca
Carcinoma, Non-Small-Cell Lung, Genes, erbB-1
09/24
09/24
Wampfler, Julian
MATAO, NCT04111978 / 2019-002264-27: MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer

Recruiting
3
540
Europe
Letrozole 2.5mg, Femara, Placebo
Swiss GO Trial Group, AGO Study Group, Arbeitsgemeinschaft Gynaekologische Onkologie Austria, Reliable Cancer Therapies, Krebsliga Schweiz, Stiftung Guido Feger, Hoffmann-La Roche, Helsana AG, Novartis Pharmaceuticals, Anticancer Fund, Belgium
Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC), Low-grade Serous Ovarian Carcinoma (LGSOC), Ovarian Endometrioid Carcinoma
10/25
10/30
NCT04381650 / 2020-004325-23: A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
49
Europe, Japan, US, RoW
TAK-981, Pembrolizumab
Takeda, Takeda Development Center Americas, Inc.
Advanced or Metastatic Solid Tumors
11/25
11/25
Zenger, Franziska
MATAO, NCT04111978 / 2019-002264-27: MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer

Recruiting
3
540
Europe
Letrozole 2.5mg, Femara, Placebo
Swiss GO Trial Group, AGO Study Group, Arbeitsgemeinschaft Gynaekologische Onkologie Austria, Reliable Cancer Therapies, Krebsliga Schweiz, Stiftung Guido Feger, Hoffmann-La Roche, Helsana AG, Novartis Pharmaceuticals, Anticancer Fund, Belgium
Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC), Low-grade Serous Ovarian Carcinoma (LGSOC), Ovarian Endometrioid Carcinoma
10/25
10/30
Cerciello, Ferdinando MD
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().

Recruiting
3
560
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen Inc.
Carcinoma, Non-Small-Cell Lung
07/26
07/28
RAISE, NCT05718323: Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

Recruiting
2
44
Europe
Niraparib
ETOP IBCSG Partners Foundation, GlaxoSmithKline, Development Limited
SCLC,Extensive Stage, SLFN11-positive
05/25
10/25
AMAZE-lung, NCT05601973 / 2021-002337-42: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

Recruiting
2
60
Europe
Amivantamab, Lazertinib, Zirabev
ETOP IBCSG Partners Foundation, Janssen Pharmaceuticals
Non Small Cell Lung Cancer
03/26
09/26
CHESS, NCT03965468 / 2018-003011-22: Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC

Recruiting
2
96
Europe
Durvalumab, Imfinzi, Carboplatin, Paclitaxel, Stereotactic body radiation therapy (SBRT), Surgical resection - definitive local treatment., Radical radiotherapy - definitive local treatment., Tremelimumab
ETOP IBCSG Partners Foundation, AstraZeneca
Non-small Cell Lung Cancer, Stage IV, Oligometastasis
08/26
12/26

Download Options